Nucleic Acid Polymer Therapy for Hepatitis B Virus: Strong Hepatitis B Surface Antigen Decline But Many Unanswered Questions

Milan Sonneveld, AJ Gehring, HL Janssen

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
14 Downloads (Pure)
Original languageEnglish
Pages (from-to)966-967
Number of pages2
Issue number3
Publication statusPublished - 1 Feb 2021

Bibliographical note

Funding Information:
Conflicts of interest The authors have made the following disclosures: MJS has received speaker's fees and research support from Roche, BMS, Gilead and Fujirebio. AJG is a consultant for GSK, Arbutus, and has received research funding from Janssen Pharmaceuticals and Gilead Sciences. HLAJ received grants from AbbVie, Arbutus, Bristol Myers Squibb, Gilead Sciences, Janssen, Medimmune, Merck, Roche, and is a consultant for Arbutus, Arena, Enyo, Gilead Sciences, GlaxoSmithKline, Janssen, Medimmune, Merck, Roche, Vir Biotechnology Inc., and Viroclinics.

Research programs

  • EMC OR-01

Cite this